CTH‑401

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameCTH‑401

Drug Alias NameTAG-72-CAR iNK cell therapyAllogeneic iPSC CAR NK cell therapyCTH‑401

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionTumor-associated glycoprotein 72 binders

TargetsTumor-associated glycoprotein 72

Therapy Area/IndicationsSolid tumoursEndometriosisOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCartherics Pty Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCartherics Pty Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursEndometriosisOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A